Abstract
Cardiovascular disease (CVD) remains the major cause of morbidity and mortality globally. Accumulating evidence indicates that coronary heart disease (CHD) contributes to the majority of cardiovascular deaths. With the development of precision medicine, the diagnosis and treatment of coronary heart disease are becoming more refined and individualized. Molecular diagnosis technology and individualized treatment are gradually applied to the clinical diagnosis and treatment of CHD. It is great significance to seek sensitive biological indicators to help early diagnosis and improve prognosis of CHD. Liquid biopsy is a minimally invasive technique, which is widely used to detect molecular biomarkers of tumors without invasive biopsy. Compared with the field of oncology, it is not easy to get the diseased tissue in CVD, especially CHD. Therefore, the idea of “fluid biopsy” is very attractive, and its progress may provide new and useful noninvasive indicators for CHD. By analyzing circulating cells or their products in blood, saliva, and urine samples, we can investigate the molecular changes that occur in each patient at a specific point in time, thus continuously monitoring the evolution of CHD. For example, the assessment of cell-free DNA (cfDNA) levels may help predict the severity of acute myocardial infarction and diagnose heart transplant rejection. Moreover, the unmethylated FAM101A gene may specifically track the cfDNA derived from cardiomyocyte death, which provides a powerful diagnostic biomarker for apoptosis during ischemia. In addition, the changes of plasma circulating miR-92 levels may predict the occurrence of acute coronary syndrome (ACS) onset in patients with diabetes. Liquid biopsy can reflect the disease state through patients’ body fluids and may noninvasively provide dynamic and rich molecular information related to CHD. It has great application potential in early warning and auxiliary diagnosis, real-time monitoring of curative effect, medication guidance and exploration of drug resistance mechanism, prognosis judgment, and risk classification of CHD. This chapter will review the latest progress of liquid biopsy in accurate diagnosis and treatment of CHD, meanwhile explore the application status and clinical prospect of liquid biopsy in CHD, in order to improve the importance of precision medicine and personalized treatment in this field.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Tsao CW (2020) Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation 141:e1–e458
中国心血管健康与疾病报告2020. 心肺血管病杂志. 2021;40:5
Fazmin IT, Achercouk Z, Edling CE, Said A, Jeevaratnam K (2020) Circulating microRNA as a biomarker for coronary artery disease. Biomol Ther 10:1354
Eggers KM, Lindahl B, Carrero JJ, Evans M, Szummer K, Jernberg T (2017) Cardiac troponins and their prognostic importance in patients with suspected acute coronary syndrome and renal dysfunction. Clin Chem 63:1409–1417
Fröhlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ (2013) Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J 34:1714–1722
Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N (2017) Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17:223–238
Huang C, Neupane YR, Lim XC, Shekhani R, Czarny B, Wacker MG, Pastorin G, Wang JW (2021) Extracellular vesicles in cardiovascular disease. Adv Clin Chem 103:47–95
Coumans FAW, Brisson AR, Buzas EI, Dignat-George F, Drees EEE, El-Andaloussi S, Emanueli C, Gasecka A, Hendrix A, Hill AF, Lacroix R, Lee Y, van Leeuwen TG, Mackman N, Mäger I, Nolan JP, van der Pol E, Pegtel DM, Sahoo S, Siljander PRM, Sturk G, de Wever O, Nieuwland R (2017) Methodological guidelines to study extracellular vesicles. Circ Res 120:1632–1648
Farinacci M, Krahn T, Dinh W, Volk HD, Düngen HD, Wagner J, Konen T, von Ahsen O (2019) Circulating endothelial cells as biomarker for cardiovascular diseases. Res Pract Thromb Haemost 3:49–58
Hosen MR, Goody PR, Zietzer A, Nickenig G, Jansen F (2020) MicroRNAs as master regulators of atherosclerosis: from pathogenesis to novel therapeutic options. Antioxid Redox Signal 33:621–644
Perakis S, Speicher MR (2017) Emerging concepts in liquid biopsies. BMC Med 15:75
Leopold JA, Loscalzo J (2018) Emerging role of precision medicine in cardiovascular disease. Circ Res 122:1302–1315
Leon-Mimila P, Wang J, Huertas-Vazquez A (2019) Relevance of multi-omics studies in cardiovascular diseases. Front Cardiovasc Med 6:91
Sara JDS, Prasad M, Zhang M, Lennon RJ, Herrmann J, Lerman LO, Lerman A (2017) High-sensitivity C-reactive protein is an independent marker of abnormal coronary vasoreactivity in patients with non-obstructive coronary artery disease. Am Heart J 190:1–11
Samman Tahhan A, Sandesara P, Hayek SS, Hammadah M, Alkhoder A, Kelli HM, Topel M, O’Neal WT, Ghasemzadeh N, Ko YA, Gafeer MM, Abdelhadi N, Choudhary F, Patel K, Beshiri A, Murtagh G, Kim J, Wilson P, Shaw L, Vaccarino V, Epstein SE, Sperling L, Quyyumi AA (2018) High-sensitivity troponin I levels and coronary artery disease severity, progression, and long-term outcomes. J Am Heart Assoc 7:e007914
Ibrahim NE, Januzzi JL Jr, Magaret CA, Gaggin HK, Rhyne RF, Gandhi PU, Kelly N, Simon ML, Motiwala SR, Belcher AM, van Kimmenade RRJ (2017) A clinical and biomarker scoring system to predict the presence of obstructive coronary artery disease. J Am Coll Cardiol 69:1147–1156
Benincasa G, Mansueto G, Napoli C (2019) Fluid-based assays and precision medicine of cardiovascular diseases: the ‘hope’ for Pandora’s box? J Clin Pathol 72:785–799
Schiano C, Rienzo M, Casamassimi A, Soricelli A, Napoli C (2017) Splicing regulators in endothelial cell differentiation. J Cardiovasc Med (Hagerstown) 18:742–749
Ziaee S, Boroumand MA, Salehi R, Sadeghian S, Hosseindokht M, Sharifi M (2018) Non-invasive diagnosis of early-onset coronary artery disease based on cell type-specific gene expression analyses. Biomed Pharmacother 108:1115–1122
Yang SW, Hennessy RR, Khosla S, Lennon R, Loeffler D, Sun T, Liu Z, Park KH, Wang FL, Lerman LO, Lerman A (2017) Circulating osteogenic endothelial progenitor cell counts: new biomarker for the severity of coronary artery disease. Int J Cardiol 227:833–839
Xu MG, Men LN, Zhao CY, Zhao X, Wang YX, Meng XC, Shen DR, Meng BY, Zhang Q, Wang T (2010) The number and function of circulating endothelial progenitor cells in patients with Kawasaki disease. Eur J Pediatr 169:289–296
Zhang B, Li D, Liu G, Tan W, Zhang G, Liao J (2021) Impaired activity of circulating EPCs and endothelial function are associated with increased Syntax score in patients with coronary artery disease. Mol Med Rep 23:321
Shim Y, Nam MH, Hyuk SW, Yoon SY, Song JM (2015) Concurrent hypermulticolor monitoring of CD31, CD34, CD45 and CD146 endothelial progenitor cell markers for acute myocardial infarction. Anal Chim Acta 853:501–507
Padfield GJ, Tura-Ceide O, Freyer E, Barclay GR, Turner M, Newby DE, Mills NL (2013) Endothelial progenitor cells, atheroma burden and clinical outcome in patients with coronary artery disease. Heart 99:791–798
Li X, Qiu J, Pan M, Zheng D, Su Y, Wei M, Kong X, Sun W, Zhu J (2015) Correlation between congenital heart disease complicated with pulmonary artery hypertension and circulating endothelial cells as well as endothelin-1. Int J Clin Exp Pathol 8:10743–10751
Watt J, Kennedy S, Ahmed N, Hayhurst J, McClure JD, Berry C, Wadsworth RM, Oldroyd KG (2016) The relationship between oxidised LDL, endothelial progenitor cells and coronary endothelial function in patients with CHD. Open Heart 3:e000342
Sun K, Jiang P, Chan KC, Wong J, Cheng YK, Liang RH, Chan WK, Ma ES, Chan SL, Cheng SH, Chan RW, Tong YK, Ng SS, Wong RS, Hui DS, Leung TN, Leung TY, Lai PB, Chiu RW, Lo YM (2015) Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A 112:E5503–E5512
Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659–1665
Polina IA, Ilatovskaya DV, DeLeon-Pennell KY (2020) Cell free DNA as a diagnostic and prognostic marker for cardiovascular diseases. Clin Chim Acta 503:145–150
Fukuda D, Nishimoto S, Aini K, Tanaka A, Nishiguchi T, Kim-Kaneyama JR, Lei XF, Masuda K, Naruto T, Tanaka K, Higashikuni Y, Hirata Y, Yagi S, Kusunose K, Yamada H, Soeki T, Imoto I, Akasaka T, Shimabukuro M, Sata M (2019) Toll-like receptor 9 plays a pivotal role in angiotensin II-induced atherosclerosis. J Am Heart Assoc 8:e010860
Tian Y, Charles EJ, Yan Z, Wu D, French BA, Kron IL, Yang Z (2019) The myocardial infarct-exacerbating effect of cell-free DNA is mediated by the high-mobility group box 1-receptor for advanced glycation end products-toll-like receptor 9 pathway. J Thorac Cardiovasc Surg 157:2256–2269.e3
Yolcu M, Dogan A, Kurtoglu N, Hancer VS, Gürbüzel M (2020) New indicator of cellular ischemia in coronary slow-flow phenomenon: cell-free DNA. Turk Kardiyol Dern Ars 48:558–565
Xie J, Yang J, Hu P (2018) Correlations of circulating cell-free DNA with clinical manifestations in acute myocardial infarction. Am J Med Sci 356:121–129
Chang CP, Chia RH, Wu TL, Tsao KC, Sun CF, Wu JT (2003) Elevated cell-free serum DNA detected in patients with myocardial infarction. Clin Chim Acta 327:95–101
Antonatos D, Patsilinakos S, Spanodimos S, Korkonikitas P, Tsigas D (2006) Cell-free DNA levels as a prognostic marker in acute myocardial infarction. Ann N Y Acad Sci 1075:278–281
Cui M, Fan M, Jing R, Wang H, Qin J, Sheng H, Wang Y, Wu X, Zhang L, Zhu J, Ju S (2013) Cell-free circulating DNA: a new biomarker for the acute coronary syndrome. Cardiology 124:76–84
Destouni A, Vrettou C, Antonatos D, Chouliaras G, Traeger-Synodinos J, Patsilinakos S, Kitsiou-Tzeli S, Tsigas D, Kanavakis E (2009) Cell-free DNA levels in acute myocardial infarction patients during hospitalization. Acta Cardiol 64:51–57
Lou X, Hou Y, Liang D, Peng L, Chen H, Ma S, Zhang L (2015) A novel Alu-based real-time PCR method for the quantitative detection of plasma circulating cell-free DNA: sensitivity and specificity for the diagnosis of myocardial infarction. Int J Mol Med 35:72–80
Wang L, Xie L, Zhang Q, Cai X, Tang Y, Wang L, Hang T, Liu J, Gong J (2015) Plasma nuclear and mitochondrial DNA levels in acute myocardial infarction patients. Coron Artery Dis 26:296–300
Bliksøen M, Mariero LH, Ohm IK, Haugen F, Yndestad A, Solheim S, Seljeflot I, Ranheim T, Andersen G, Aukrust P, Valen G, Vinge LE (2012) Increased circulating mitochondrial DNA after myocardial infarction. Int J Cardiol 158:132–134
Shimony A, Zahger D, Gilutz H, Goldstein H, Orlov G, Merkin M, Shalev A, Ilia R, Douvdevani A (2010) Cell free DNA detected by a novel method in acute ST-elevation myocardial infarction patients. Acute Card Care 12:109–111
Zemmour H, Planer D, Magenheim J, Moss J, Neiman D, Gilon D, Korach A, Glaser B, Shemer R, Landesberg G, Dor Y (2018) Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA. Nat Commun 9:1443
Borissoff JI, Joosen IA, Versteylen MO, Brill A, Fuchs TA, Savchenko AS, Gallant M, Martinod K, Ten Cate H, Hofstra L, Crijns HJ, Wagner DD, Kietselaer B (2013) Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol 33:2032–2040
de Nigris F, Cacciatore F, Mancini FP, Vitale DF, Mansueto G, D’Armiento FP, Schiano C, Soricelli A, Napoli C (2018) Epigenetic hallmarks of fetal early atherosclerotic lesions in humans. JAMA Cardiol 3:1184–1191
Agha G, Mendelson MM, Ward-Caviness CK, Joehanes R, Huan T, Gondalia R, Salfati E, Brody JA, Fiorito G, Bressler J, Chen BH, Ligthart S, Guarrera S, Colicino E, Just AC, Wahl S, Gieger C, Vandiver AR, Tanaka T, Hernandez DG, Pilling LC, Singleton AB, Sacerdote C, Krogh V, Panico S, Tumino R, Li Y, Zhang G, Stewart JD, Floyd JS, Wiggins KL, Rotter JI, Multhaup M, Bakulski K, Horvath S, Tsao PS, Absher DM, Vokonas P, Hirschhorn J, Fallin MD, Liu C, Bandinelli S, Boerwinkle E, Dehghan A, Schwartz JD, Psaty BM, Feinberg AP, Hou L, Ferrucci L, Sotoodehnia N, Matullo G, Peters A, Fornage M, Assimes TL, Whitsel EA, Levy D, Baccarelli AA (2019) Blood leukocyte DNA methylation predicts risk of future myocardial infarction and coronary heart disease. Circulation 140:645–657
Zhong J, Agha G, Baccarelli AA (2016) The role of DNA methylation in cardiovascular risk and disease: methodological aspects, study design, and data analysis for epidemiological studies. Circ Res 118:119–131
Schiano C, Vietri MT, Grimaldi V, Picascia A, De Pascale MR, Napoli C (2015) Epigenetic-related therapeutic challenges in cardiovascular disease. Trends Pharmacol Sci 36:226–235
Zhou MY, Yang JM, Xiong XD (2018) The emerging landscape of circular RNA in cardiovascular diseases. J Mol Cell Cardiol 122:134–139
Ayupe AC, Reis EM (2017) Evaluating the stability of mRNAs and noncoding RNAs. Methods Mol Biol 1468:139–153
Tang Y, Bao J, Hu J, Liu L, Xu DY (2021) Circular RNA in cardiovascular disease: expression, mechanisms and clinical prospects. J Cell Mol Med 25:1817–1824
Altesha MA, Ni T, Khan A, Liu K, Zheng X (2019) Circular RNA in cardiovascular disease. J Cell Physiol 234:5588–5600
Zhao Z, Li X, Gao C, Jian D, Hao P, Rao L, Li M (2017) Peripheral blood circular RNA hsa_circ_0124644 can be used as a diagnostic biomarker of coronary artery disease. Sci Rep 7:39918
Wang L, Shen C, Wang Y, Zou T, Zhu H, Lu X, Li L, Yang B, Chen J, Chen S, Lu X, Gu D (2019) Identification of circular RNA Hsa_circ_0001879 and Hsa_circ_0004104 as novel biomarkers for coronary artery disease. Atherosclerosis 286:88–96
Holdt LM, Stahringer A, Sass K, Pichler G, Kulak NA, Wilfert W, Kohlmaier A, Herbst A, Northoff BH, Nicolaou A, Gäbel G, Beutner F, Scholz M, Thiery J, Musunuru K, Krohn K, Mann M, Teupser D (2016) Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun 7:12429
Salgado-Somoza A, Zhang L, Vausort M, Devaux Y (2017) The circular RNA MICRA for risk stratification after myocardial infarction. Int J Cardiol Heart Vasc 17:33–36
Mao YY, Wang JQ, Guo XX, Bi Y, Wang CX (2018) Circ-SATB2 upregulates STIM1 expression and regulates vascular smooth muscle cell proliferation and differentiation through miR-939. Biochem Biophys Res Commun 505:119–125
Simo-Cheyou ER, Tan JJ, Grygorczyk R, Srivastava AK (2017) STIM-1 and ORAI-1 channel mediate angiotensin-II-induced expression of Egr-1 in vascular smooth muscle cells. J Cell Physiol 232:3496–3509
Owens GK, Kumar MS, Wamhoff BR (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84:767–801
Li M, Ding W, Tariq MA, Chang W, Zhang X, Xu W, Hou L, Wang Y, Wang J (2018) A circular transcript of ncx1 gene mediates ischemic myocardial injury by targeting miR-133a-3p. Theranostics 8:5855–5869
Wang K, Gan TY, Li N, Liu CY, Zhou LY, Gao JN, Chen C, Yan KW, Ponnusamy M, Zhang YH, Li PF (2017) Circular RNA mediates cardiomyocyte death via miRNA-dependent upregulation of MTP18 expression. Cell Death Differ 24:1111–1120
Huang S, Li X, Zheng H, Si X, Li B, Wei G, Li C, Chen Y, Chen Y, Liao W, Liao Y, Bin J (2019) Loss of super-enhancer-regulated circRNA Nfix induces cardiac regeneration after myocardial infarction in adult mice. Circulation 139:2857–2876
Zhou SS, Jin JP, Wang JQ, Zhang ZG, Freedman JH, Zheng Y, Cai L (2018) miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges. Acta Pharmacol Sin 39:1073–1084
Zhang L, Zhang Y, Zhao Y, Wang Y, Ding H, Xue S, Li P (2018) Circulating miRNAs as biomarkers for early diagnosis of coronary artery disease. Expert Opin Ther Pat 28:591–601
Wang W, Li Z, Zheng Y, Yan M, Cui Y, Jiang J (2019) Circulating microRNA-92a level predicts acute coronary syndrome in diabetic patients with coronary heart disease. Lipids Health Dis 18:22
Tabuchi T, Satoh M, Itoh T, Nakamura M (2012) MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. Clin Sci (London, England : 1979) 123:161–171
Takahashi Y, Satoh M, Minami Y, Tabuchi T, Itoh T, Nakamura M (2010) Expression of miR-146a/b is associated with the toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and toll-like receptor 4 levels. Clin Sci (London, England : 1979) 119:395–405
Lawson C, Vicencio JM, Yellon DM, Davidson SM (2016) Microvesicles and exosomes: new players in metabolic and cardiovascular disease. J Endocrinol 228:R57–R71
Jansen F, Nickenig G, Werner N (2017) Extracellular vesicles in cardiovascular disease: potential applications in diagnosis, prognosis, and epidemiology. Circ Res 120:1649–1657
Davidson SM, Yellon DM (2018) Exosomes and cardioprotection – a critical analysis. Mol Asp Med 60:104–114
Alexandru N, Andrei E, Niculescu L, Dragan E, Ristoiu V, Georgescu A (2017) Microparticles of healthy origins improve endothelial progenitor cell dysfunction via microRNA transfer in an atherosclerotic hamster model. Acta Physiol (Oxf) 221:230–249
Alexandru N, Andrei E, Safciuc F, Dragan E, Balahura AM, Badila E, Georgescu A (2020) Intravenous administration of allogenic cell-derived microvesicles of healthy origins defend against atherosclerotic cardiovascular disease development by a direct action on endothelial progenitor cells. Cell 9:423
Zhao J, Li X, Hu J, Chen F, Qiao S, Sun X, Gao L, Xie J, Xu B (2019) Mesenchymal stromal cell-derived exosomes attenuate myocardial ischaemia-reperfusion injury through miR-182-regulated macrophage polarization. Cardiovasc Res 115:1205–1216
Wang Y, Zhang L, Li Y, Chen L, Wang X, Guo W, Zhang X, Qin G, He SH, Zimmerman A, Liu Y, Kim IM, Weintraub NL, Tang Y (2015) Exosomes/microvesicles from induced pluripotent stem cells deliver cardioprotective miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium. Int J Cardiol 192:61–69
Maring JA, Lodder K, Mol E, Verhage V, Wiesmeijer KC, Dingenouts CKE, Moerkamp AT, Deddens JC, Vader P, Smits AM, Sluijter JPG, Goumans MJ (2019) Cardiac progenitor cell-derived extracellular vesicles reduce infarct size and associate with increased cardiovascular cell proliferation. J Cardiovasc Transl Res 12:5–17
Gallet R, Dawkins J, Valle J, Simsolo E, de Couto G, Middleton R, Tseliou E, Luthringer D, Kreke M, Smith RR, Marbán L, Ghaleh B, Marbán E (2017) Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction. Eur Heart J 38:201–211
Vicencio JM, Yellon DM, Sivaraman V, Das D, Boi-Doku C, Arjun S, Zheng Y, Riquelme JA, Kearney J, Sharma V, Multhoff G, Hall AR, Davidson SM (2015) Plasma exosomes protect the myocardium from ischemia-reperfusion injury. J Am Coll Cardiol 65:1525–1536
Gu H, Liu Z, Li Y, Xie Y, Yao J, Zhu Y, Xu J, Dai Q, Zhong C, Zhu H, Ding S, Zhou L (2018) Serum-derived extracellular vesicles protect against acute myocardial infarction by regulating miR-21/PDCD4 signaling pathway. Front Physiol 9:348
Liu J, Jiang M, Deng S, Lu J, Huang H, Zhang Y, Gong P, Shen X, Ruan H, Jin M, Wang H (2018) miR-93-5p-containing exosomes treatment attenuates acute myocardial infarction-induced myocardial damage. Mol Ther Nucleic Acids 11:103–115
Luo Q, Guo D, Liu G, Chen G, Hang M, Jin M (2017) Exosomes from MiR-126-overexpressing Adscs are therapeutic in relieving acute myocardial Ischaemic injury. Cell Physiol Biochem 44:2105–2116
Pan J, Alimujiang M, Chen Q, Shi H, Luo X (2019) Exosomes derived from miR-146a-modified adipose-derived stem cells attenuate acute myocardial infarction-induced myocardial damage via downregulation of early growth response factor 1. J Cell Biochem 120:4433–4443
Jansen F, Yang X, Proebsting S, Hoelscher M, Przybilla D, Baumann K, Schmitz T, Dolf A, Endl E, Franklin BS, Sinning JM, Vasa-Nicotera M, Nickenig G, Werner N (2014) MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. J Am Heart Assoc 3:e001249
Yang Y, Li Y, Chen X, Cheng X, Liao Y, Yu X (2016) Exosomal transfer of miR-30a between cardiomyocytes regulates autophagy after hypoxia. J Mol Med (Berl) 94:711–724
Matsumoto S, Sakata Y, Suna S, Nakatani D, Usami M, Hara M, Kitamura T, Hamasaki T, Nanto S, Kawahara Y, Komuro I (2013) Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ Res 113:322–326
Agrawal H, Choy HK, Liu J, Auyoung M, Albert MA (2020) Coronary artery disease. Arterioscler Thromb Vasc Biol 40:e185–e192
Saenz-Pipaon G, Martinez-Aguilar E, Orbe J, González Miqueo A, Fernandez-Alonso L, Paramo JA, Roncal C (2021) The role of circulating biomarkers in peripheral arterial disease. Int J Mol Sci 22:3601
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Zhu, W., Li, X. (2023). Liquid Biopsy in Coronary Heart Disease. In: Huang, T., Yang, J., Tian, G. (eds) Liquid Biopsies. Methods in Molecular Biology, vol 2695. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3346-5_19
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3346-5_19
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3345-8
Online ISBN: 978-1-0716-3346-5
eBook Packages: Springer Protocols